Alzheimer's drug trials to take different approach
Timing might be everything when it comes to treating Alzheimer's disease, according to research being presented on Monday at a meeting of the American Neurological Association in Boston.
There is no cure for the disease, which affects more than 5 million people in the country, and numbers are expected to triple by 2050.
Researchers will discuss findings on two large drug trials. Results announced last summer found that they failed to improve cognition or daily functioning compared with a placebo. The bapineuzumab and solanezumab therapies were done on patients with mild to moderate dementia. The drugs target beta amyloid, a protein in the brain believed to cause the disease.
“We think we've been starting trials too late in the progression of the disease,” said Laurie Ryan of the National Institute on Aging.
Scientists are discovering mechanisms of the disease and how it progresses. A large study in the New England Journal of Medicine found that brain changes begin as early as 25 years before the onset of symptoms.
“I'm worried that we're intervening too late and with too little” of the drugs, said Reisa Sperling of Brigham and Women's Hospital in Boston.
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.
- Residents in Seattle: Compost or else ...
- Number of children on food stamps hits 6-year high
- Treasure hunter accused of swindling investors captured
- Federal Highway Trust Fund running on empty
- Police to Waze: Not so fast on cop tracker, which they say makes it harder to catch speeders
- Poll finds most Americans want health insurance subsidies restored if Supreme Court votes against Obamacare provision
- Deadly fire in Maryland started in faulty electrical outlet, spread to Christmas tree
- Arkansas rejects proposal to celebrate Gen. Lee, MLK on different days
- DEA says scanning of license plates near gun shows off
- N.D. didn’t inspect pipe before rupture
- Prosecutors fight new try to relocate Boston trial